What actually happens during gene therapy for Wilson disease, and does it hurt?

Gene therapy for Wilson disease is still in clinical trials as of 2025, but it has advanced far enough that real patients have received it, and the question of what the experience actually involves is entirely reasonable. This page describes how current gene therapy approaches work in practice — the procedure, what to expect physically, and what the weeks around it look like. This is not the same as standard Wilson disease treatment; it is an investigational approach available only at a small number of research centres through formal trials.¹

The basic idea: delivering a working copy of ATP7B

Wilson disease is caused by mutations in the ATP7B gene, which encodes a protein that moves copper out of liver cells.² Without a working copy, copper accumulates. Gene therapy attempts to deliver a functional version of that gene directly into liver cells, so they can start making the protein and handling copper normally.

The delivery vehicle used in current Wilson disease trials is an adeno-associated virus, or AAV. This is a small, naturally occurring virus that has been modified so it cannot replicate or cause disease — it is essentially an empty shell carrying a therapeutic payload. When injected into the bloodstream, AAV vectors are designed to target liver cells (hepatocytes), enter them, and release the functional ATP7B gene.³

If it works as intended, the liver cells begin producing the ATP7B protein themselves, and copper metabolism normalizes — potentially without ongoing daily medication.

What the actual procedure looks like

Before infusion day: Participants undergo extensive screening — liver biopsies in some trials, blood tests, imaging, and genetic confirmation of their specific ATP7B mutation. You will likely also be tested for pre-existing antibodies against the AAV serotype being used, because existing immunity can reduce the therapy’s effectiveness or increase immune reactions.

In the days before infusion, some protocols require corticosteroids (steroid tablets) to reduce the risk of an immune response to the AAV vector. This is a standard precaution in AAV gene therapy across conditions, not specific to Wilson disease.³

The infusion itself: Gene therapy is administered as a single intravenous infusion — an IV drip, the same route as many hospital medications. You sit or lie in a treatment chair or bed, a cannula is placed in a vein (usually in the arm), and the vector is infused slowly over one to several hours.

The procedure is not painful beyond the initial IV placement. Most patients describe it as similar to any other IV treatment — sometimes boring, occasionally accompanied by minor infusion reactions (flushing, low-grade fever, headache) that are managed by the medical team in real time. You are closely monitored throughout: blood pressure, heart rate, and oxygen saturation are checked continuously. If there is any significant reaction, the infusion can be slowed or paused.

After infusion: You typically remain in the unit for several hours of observation. Many trials require an overnight stay. You do not go home the same afternoon feeling dramatically different — the therapy takes time to express itself in your liver cells, and any benefit builds gradually over weeks to months.

What the monitoring period involves

The period after infusion is actually more demanding than the infusion day itself. Gene therapy trials require intensive follow-up because:

• Immune responses to the AAV vector can occur days to weeks after infusion, particularly affecting liver enzymes. Corticosteroids are often continued and may need to be tapered over weeks or months depending on how your liver function responds.
• Liver enzyme monitoring (ALT, AST) is done very frequently in the first weeks — sometimes weekly — to catch early signs of immune-mediated liver inflammation.
• Copper markers (serum copper, ceruloplasmin, 24-hour urine copper) are followed to assess whether the therapy is actually working.
• Your existing Wilson disease medications are usually continued unchanged during the initial period, because it takes time to determine whether the therapy has been effective enough to reduce or eliminate the need for them.¹

Trials also typically include long-term follow-up spanning years, because the durability of the benefit — how long the therapeutic gene remains active in liver cells — is one of the key questions being studied.

Is there a risk of serious complications?

Yes, and trial participants are fully informed of these before consenting. The main risks include:

Immune reactions: The immune system may recognize the AAV capsid (shell) as foreign and mount a response. This can range from mild (low fever, elevation of liver enzymes) to, in rare cases, more severe liver inflammation. This is the reason corticosteroids are used prophylactically and why liver monitoring is so intensive post-infusion.³

Insertional risk: AAV vectors primarily remain in cells as episomes (floating genetic material) rather than integrating into chromosomes, which reduces but does not eliminate the theoretical risk of disrupting other genes. Long-term cancer surveillance is built into trial follow-up protocols for this reason.

Uncertain durability: Liver cells divide, especially in younger patients, and non-integrating gene therapy may lose effectiveness over years as cells turn over. This is a known limitation and an active area of research.¹

Pre-existing AAV immunity: If you have natural antibodies against the AAV serotype being used, you may be excluded from a trial or be at higher risk of immune complications. This is assessed during screening.

Who can participate, and how to find a trial

Gene therapy for Wilson disease is not available as routine treatment. As of mid-2025, it is accessible only through formal clinical trials at participating academic medical centres. The primary registry listing active trials is ClinicalTrials.gov — searching “Wilson disease gene therapy” or “ATP7B gene therapy” there will show what is currently enrolling and where.

Your Wilson specialist is the best first contact. They can assess your eligibility, discuss whether your current disease status makes you a reasonable candidate (trials typically want patients who are medically stable enough to undergo the procedure safely), and refer you to a participating centre if there is one accessible to you.²

One realistic expectation to set: gene therapy trials are scientifically important but the administrative process — screening, consent, travel to a specialist centre, and intensive follow-up commitments — is substantial. It is not the right choice for every patient, and that is a decision to make with your team based on your full situation.

For context on current standard treatments, see our medications overview. If you have questions about what to bring up with your doctor, what to tell your doctor may also be useful.

This page is patient education, not medical advice. Gene therapy for Wilson disease is experimental. Any interest in participating in a clinical trial should be discussed with your Wilson disease specialist, who can review your eligibility and connect you with appropriate research centres.

References